NCT02963935 - Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Biotech Hunter

Enrollment

282

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

May 23, 2018

Study Completion Date

June 19, 2018

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

liraglutide

Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

DRUG

placebo

Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

BEHAVIORAL

CMS Intensive Behavior Therapy

Intensive Behaviour Therapy for obesity

Trial Locations (10)

Novo Nordisk Investigational Site, Arlington

Novo Nordisk Investigational Site, Greensboro

Novo Nordisk Investigational Site, Salisbury

Novo Nordisk Investigational Site, Charleston

Novo Nordisk Investigational Site, Jacksonville

Novo Nordisk Investigational Site, Plantation

Novo Nordisk Investigational Site, Wadsworth

Novo Nordisk Investigational Site, Chicago

Novo Nordisk Investigational Site, Dallas

Novo Nordisk Investigational Site, Philadelphia